natgillin/translations-raw huggingface dataset:
dose knob pushed in and ready to reset
gumb za doziranje je utisnut i spreman za novo namještanje
Dose Knob with burgundy ring
Gumb za doziranje
Dose Knob: Dark grey with burgundy ring on the end
Gumb za doziranje: tamnosiv sa tamnocrvenim prstenom na rubu
Dose Knob: Light grey with green ring on the end
Gumb za doziranje: svjetlosiv sa zelenim prstenom na rubu
dose level -1 (100 mg/m2 ) still results in unacceptable toxicity the same Grade 3 non-haematological toxicity (except for alopecia, nausea, vomiting) recurs after dose reduction.
ako razina doze -1 (100 mg/m2) i dalje dovodi do neprihvatljivih toksičnih učinaka ako se nakon smanjenja doze ponovno jave isti nehematološki toksični učinci stupnja 3 (osim alopecije, mučnine i povraćanja)
dose level -1 (100 mg/m2) still results in unacceptable toxicity the same Grade 3 non-haematological toxicity (except for alopecia, nausea, vomiting) recurs after dose reduction.
ako razina doze -1 (100 mg/m2) i dalje proizvodi neprihvatljive toksične učinke ako se nakon smanjenja doze ponovno jave isti nehematološki toksični učinci stupnja 3 (osim alopecije, mučnine i povraćanja)
dose level -1 (100 mg/m2) still results in unacceptable toxicity the same Grade 3 non-haematological toxicity (except for alopecia, nausea, vomiting) recurs after dose reduction.
ako razina doze -1 (100 mg/m2) i dalje proizvodi neprihvatljive toksične učinke ako se nakon smanjenja doze ponovno jave isti nehematološki toksični učinci stupnja 3 (osim alopecije, mučnine i povraćanja).
dose level -1 (100 mg/m²) still results in unacceptable toxicity the same Grade 3 non-haematological toxicity (except for alopecia, nausea, vomiting) recurs after dose reduction.
ako razina doze -1 (100 mg/m2) i dalje stvara neprihvatljive toksične učinke ako se nakon smanjenja doze ponovno jave isti nehematološki toksični učinci stupnja 3 (osim alopecije, mučnine i povraćanja)
Dose level -1*
1. razina doze
Dose level -1*
Početna doza
Dose level -2*
2. razina doze
Dose Level -4
4. razina doze
Dose Level -5
5. razina doze
Dose Level 1
1. razina doze
Dose level 1000 mg/m (twice daily)
Doza od 1000 mg/m2 (dvaput dnevno)
Dose level 1250 mg/m (twice daily)
Doza od 1250 mg/m2 (dvaput dnevno)
Dose level 1250 mg/m2 (twice daily)
Doza od 1000 mg/m2 (dvaput dnevno)
Dose Level 2
2. razina doze
Dose Level 3
3. razina doze
Dose Level 3
3.razina doze 3
Dose Level 4
4. razina doze
Dose Level 5
5. razina doze
Dose level-5
5. razina doze
Dose limitation of other statins, metabolised by CYP3A4 (e.g lovastatin), may be considered when taking Ranexa.
Kod bolesnika koji uzimaju Ranexu treba razmotriti ograničenje doza drugih statina koji se metaboliziraju CYP3A4 enzimima (npr. lovastatin).
Dose limiting toxicities include diarrhoea and dehydration.
Toksičnosti koje ograničavaju dozu uključuju proljev i dehidraciju.
Dose limiting toxicities include diarrhoea, abdominal pain, nausea, stomatitis and hand-foot syndrome (hand-foot skin reaction, palmar-plantar erythrodysesthesia).
Toksičnost koja ograničava dozu uključuje proljev, bol u abdomenu, mučninu, stomatitis i sindrom šaka-stopalo (kožna reakcija na šakama i stopalima, palmarno-plantarna eritrodisestezija).
Dose limiting toxicities of NovoSeven have not been investigated in clinical trials.
Granična toksična doza lijeka NovoSeven nije ispitivana u kliničkim ispitivanjima.
Dose management considerations
Na što treba paziti u doziranju
Dose modification advice for Cotellic when used with vemurafenib
Savjeti za prilagodbu doze lijeka Cotellic kod primjene s vemurafenibom
Dose modification advice for left ventricular dysfunction
Savjeti za prilagodbu doze kod disfunkcije lijeve klijetke
Dose modification and reinitiation of therapy for infusion related ADRs – in patients with previously untreated CLL and refractory CLL.
Prilagodba doze i ponovno započinjanje terapije kod nuspojava povezanih s infuzijom – u bolesnika s prethodno neliječenim KLL-om i refraktornim KLL-om
Dose modification at day 1 of cycle subsequent to AE
Prilagodba doze 1. dana ciklusa nakon nastupa nuspojave
Dose modification based on elevated hepatic aminotransferases
Prilagodba doze na temelju povišenih jetrenih aminotransferaza
Dose modification for all patients
Prilagodba doze za sve bolesnike
Dose modification for all patients (monotherapy and combination therapy)
Prilagođavanje doze za sve bolesnike (monoterapija i kombinirana terapija)
Dose modification of calcium channel blockers should be considered when co- administered with indinavir/ritonavir as it may result in an increased response.
Treba razmotriti prilagodbu doze blokatora kalcijevih kanala kad se primjenjuju istodobno s indinavirom/ritonavirom jer može doći do pojačanog odgovora.
Dose modification of Daklinza to manage adverse reactions is not recommended.
Ne preporučuje se prilagođavanje doze lijeka Daklinza radi zbrinjavanja nuspojava.
Dose modification of NULOJIX is not recommended for a change in body weight of less than 10%.
Ne preporučuje se prilagođavati dozu lijeka NULOJIX kod promjene tjelesne težine manje od 10%.
Dose modification of NULOJIX is not recommended for a change in body weight of less than 10%.
Ne preporučuje se prilagođivati dozu lijeka NULOJIX kod promjene tjelesne težine manje od 10%.
Dose modification of ribavirin in patients taking 1,000-1,200 mg daily
Prilagodba doze ribavirina u pacijenata koji uzimaju 1000-1200 mg na dan
Dose modification should be in 200 mg increments in a stepwise fashion based on individual tolerability in order to manage adverse reactions.
Kako bi se kontrolirale nuspojave, prilagodbu doze treba raditi postupno, po 200 mg prema individualnoj podnošljivosti.
Dose modification, interruption and discontinuation
Prilagodba doze, privremen prekid primjene i obustava liječenja
Dose modifications
Prilagođavanje doze
Dose modifications (interruptions or reductions) for rash and diarrhoea were needed in 11% and 7% of patients, respectively.
Promjene u doziranju (privremeni prekid ili smanjenje doze) bili su potrebni u 11% bolesnika zbog osipa te u 7% bolesnika zbog proljeva.
Dose modifications (interruptions or reductions) for rash and diarrhoea were needed in 8.3% and 3% of patients, respectively, in study BO18192 and 5.6% and 2.8% of patients, respectively, in study BO25460.
Prilagodbe doze (prekidi ili smanjenja) zbog osipa i proljeva bile su potrebne u 8,3% odnosno 3% bolesnika u ispitivanju BO18192 te u 5,6% odnosno 2,8% bolesnika u ispitivanju BO25460.
Dose modifications are not recommended for adverse reactions of cutaneous squamous cell carcinoma (cuSCC) or new primary melanoma (see dabrafenib SmPC for further details).
Prilagodbe doze ne preporučuje se kod nuspojava u obliku planocelularnog karcinoma kože (eng. cutaneous squamous cell carcinoma, cuSCC) ili novog primarnog melanoma (vidjeti Sažetak opisa svojstava lijeka za dabrafenib za dodatne pojedinosti).
Dose modifications due to anaemia/hemolytic anaemia occurred twice as often in patients treated with the combination of Victrelis with peginterferon alfa-2b and ribavirin (26%) compared to peginterferon alfa-2b and ribavirin alone (13%).
Prilagodba doze zbog anemije/hemolitičke anemije bila je potrebna dvostruko češće u bolesnika liječenih kombinacijom lijeka Victrelis s peginterferonom alfa-2b i ribavirinom (26%), u usporedbi s liječenjem samo peginterferonom alfa-2b i ribavirinom (13%).
Dose modifications due to peripheral neuropathy are described in Table 2.
Promjene doze zbog periferne neuropatije prikazane su u tablici 2.
Dose modifications during treatment (all indications)
Prilagodbe doze tijekom liječenja (sve indikacije)
Dose modifications for haematologic toxicities
Prilagodbe doze zbog hematološke toksičnosti
Dose modifications for hematologic toxicity on days 8 and 15 of any cycle
Prilagodba doze zbog hematološke toksičnosti 8. i 15. dana bilo kojeg ciklusa liječenja
Dose modifications for renal toxicities
Prilagodbe doze zbog bubrežne toksičnosti
Dose modifications for Teysuno for adverse reactions in general except for haematologic and renal toxicities
Prilagodbe doza lijeka Teysuno zbog nuspojava općenito, osim zbog hematološke i bubrežne toksičnosti
Dose modifications of each component of FOLFIRI should be made independently and are provided in Table 4.
Prilagodbe doze svake pojedine sastavnice protokola FOLFIRI treba provoditi neovisno o drugim sastavnicama, sukladno napucima u Tablici 4.
Dose modifications should be applied for the precipitating adverse reaction as necessary (see section 4.2).
U slučaju nuspojave uslijed precipitacije, treba prilagoditi dozu prema potrebi (vidjeti dio 4.2).
Dose modifications should be made if patients experience the following adverse reactions (Grades refer to Common Terminology Criteria for Adverse Events [CTCAE 4.0]):
Dozu je potrebno prilagoditi ako se u bolesnika pojave sljedeće nuspojave (stupnjevi su određeni prema verziji 4,0 Zajedničkih terminoloških kriterija za nuspojave (engl.
Dose modify concomitant DMARDs if appropriate.
Ako je moguće, prilagodite dozu istodobno primijenjenih DMARD-ova.
Dose Normalized to 1 mg/kg Mean ± SD Tigecycline Cmax and AUC in Children
Srednje vrijednosti ± SD Cmax i AUC tigeciklina u djece pri dozi normaliziranoj do 1 mg/kg
Dose obtained
Doza je primjerena
dose of
CYP3A4
dose of
doza
Dose of 0.2 mg meloxicam/kg body weight: 12 drops/kg body weight Dose of 0.1 mg meloxicam/kg body weight: 6 drops/kg body weight Dose of 0.05 mg meloxicam/kg body weight: 3 drops/kg body weight.
Doza od 0,2 mg meloksikama/kg tjelesne mase: 12 kapi /kg tjelesne mase Doza od 0,1 mg meloksikama/kg tjelesne mase: 6 kapi /kg tjelesne mase Doza od 0,05 mg meloksikama/kg tjelesne mase: 3 kapi /kg tjelesne mase
Dose of 5 mg ceftiofur/kg bodyweight (equivalent to 1 ml of NAXCEL per 20 kg bodyweight) administered once in the neck by intramuscular injection.
Doza od 5 mg ceftiofura/kg tjelesne težine (odgovara 1 ml NAXCELA na 20 kg tjelesne težine) daje se jedanput u vrat intramuskularnom injekcijom.
Dose of Abraxane (mg/m2)1
Doza lijeka Abraxane (mg/m2)1
Dose of active substance
Doza djelatne tvari
Dose of ALIMTA (mg/m2)
NCI 1998).
Dose of caffeine citrate (Volume)
Doza kofein- citrata (volumen)
Dose of ceftazidime/avibactam
ceftazidima/avibaktama
Dose of CIAMBRA (mg/m2)
Doza lijeka CIAMBRA (mg/m2)
Dose of Co- administered
Doza istodobno primijenjenog lijeka (mg)
Dose of Co- administered Medicinal Product (mg)
Doza istodobno primijenjeno g lijeka (mg)
Dose of Co- administered Medicinal Product (mg)
Doza istodobno primijenjenog lijeka (mg)
Dose of Co-administered Medicinal Product (mg)
Doza istodobno primijenjenog lijeka (mg)
Dose of Ebilfumin
Doza lijeka Ebilfumin
dose of elvitegravir should be 150 mg once daily.
elvitegravira mora biti 150 mg jedanput
Dose of iloprost at
Doza iloprosta
Dose of Levemir should be adjusted individually.
Dozu lijeka Levemir treba prilagoditi potrebama pojedinog bolesnika.
Dose of NORVIR
Doza lijeka NORVIR
Dose of NORVIR
Doza lijeka NORVIR (mg)
Dose of Pemetrexed Hospira (mg/m2)
Doza lijeka Pemetreksed Hospira (mg/m2)
Dose of premetrexed (mg/m²)
Doza pemetrekseda (mg/m²)
Dose of Tamiflu
Doza lijeka Tamiflu
dose of the sedatives/hypnotics
(parenteralni)
dose of the sedatives/hypnotics
ljedeće doze: jednokratna doza
dose of trazodone may be considered.
moraju razmotriti niže doze trazodona.
Dose of Tybost
Doza lijeka Tybost
Dose of Vitekta
Doza lijeka Vitekta
Dose or dose interval adjustment is required in all patients with creatinine clearance < 30 ml/min (see sections 4.2, 4.4 and 5.2).
PrilagoĎavanje doze ili intervala doziranja obavezno je za pacijente s klirensom kreatinina < 30 ml/min (vidjeti dijelove 4.2, 4.4 i 5.2).
Dose Orfadin
Doza Orfadina
Dose Orfadin
Orfadina
Dose pack contents
Sadržaj dozirnog pakiranja
Dose per administration
Doza po jednoj
Dose per bid injection (mg/dose)
Doza po injekciji koja se primjenjuje dvaput na dan (mg/dozi)
Dose preparation guide (underside of the dose tray)
Vodilice za pripremu doze (s donje strane posude)
dose primary schedule
Primarna imunizacija s 2 doze
Dose proportionality from 100 micrograms to 1000 micrograms has been demonstrated.
Dokazana je proporcionalnost doze od 100 mikrograma do 1000 mikrograma.
Dose proportionality has been demonstrated from 25 to 60 micrograms per dose.
Dokazana je proporcionalnost doze od 25 do 60 mikrograma po dozi.
Dose proportionality has not been established in patients.
Proporcionalnost doza nije utvrđena u bolesnika.
Dose proportionality in total exposure is observed after subcutaneous administration within the therapeutic dose range.
Proporcionalnost doze u ukupnoj izloženosti utvrđena je nakon supkutane primjene unutar raspona terapijske doze.
Dose proportionality was established in children for the investigated doses of 90 and 180 µg per kg body weight, which is in accordance with previous findings at lower doses (17.5 – 70 µg/kg rFVIIa).
Utvrđena je proporcionalnost s obzirom na dozu u djece za ispitivane doze od 90 i 180 µg po kg tjelesne težine, što odgovara ranijim nalazima pri nižim dozama (17,5 - 70 µg/kg rFVIIa).
Dose proportionality was shown by increase of nintedanib exposure (dose range 50 - 450 mg once daily and 150 - 300 mg twice daily).
Proporcionalnost doze pokazala se povećanjem izloženosti nintedanibu (raspon doze 50-450 mg jedanput dnevno i 150 – 300 mg dvaput dnevno).
Dose rate (mg/kg bodyweight) x bodyweight (kg)
Doza (mg/kg tjelesne mase) x tjelesna masa (kg)
Dose rate (mg/kg bodyweight) x bodyweight (kg)
doza (mg/kg tjelesne mase) x tjelesna mase (kg)
Dose rate (nSv/h)
Doza zračenja (nSv/h)
Dose rate(mg/kg bodyweight)
Doza (mg/kg tjelesne mase)
Dose recommendation
Preporučeno doziranje
Dose recommendation for patients with one or more of the following clinical factors:
Preporučena doza za bolesnike s jednim ili više od sljedećih kliničkih čimbenika:
Dose recommendations for children and adolescents are based on PK modelling.
Preporučene doze za djecu i adolescente temelje se na farmakokinetičkom modeliranju.
Dose reduce and resume lenvatinib
Sniženje doze i nastavak primjene lenvatiniba
Dose reduction
Metadon (32-100 mg QD)
Dose reduction and/or temporary interruption of Stivarga, or in severe or persistent cases, permanent discontinuation of Stivarga should be considered (see section 4.2).
Mora se razmotriti smanjenje doze i/ili privremeni prekid primjene lijeka Stivarga, ili u teškim ili tvrdokornim slučajevima, trajni prekid liječenja lijekom Stivarga (vidjeti dio 4.2).
dose reduction can be made;
sniženje doze; stoga je potreban
Dose reduction for parenterally administered
Potrebno je razmotriti smanjenje doze
Dose reduction guidelines for haematological and non- haematological toxicities are provided in Tables 1 and 2.
Smjernice za smanjenje doze u slučaju hematološke i nehematološke toksičnosti navedene su u Tablicama 1 i 2.
dose reduction is
praćenje i smanjenje doze
Dose reduction is not recommended.
Ne preporučuje se smanjivati dozu.
Dose reduction is recommended for patients with moderate or severe renal impairment (see sections 4.2 and 5.2).
Preporučuje se smanjivanje doza u bolesnika s umjerenim ili teškim oštećenjem funkcije bubrega (vidjeti dijelove 4.2 i 5.2).
Dose reduction led to improvement of signs and symptoms in all these patients (positive dechallenge), suggesting a causal relationship with cysteamine administration.
Smanjenje doze dovelo je do poboljšanja znakova i simptoma u svih bolesnika (pozitivan dechallenge), što upućuje na povezanost s primjenom cisteamina.
Dose reduction level
Sniženje razine doze
Dose reduction levels
Sniženja razine doze
Dose reduction levels (> 75 years of age): Starting dose 20 mg; dose level -1 12 mg; dose level-2 8 mg on Days 1, 8, 15 and 22 of each 28-day treatment cycle.
Razine smanjenja doze (dob >75 godina): početna doza 20 mg; 1. razina doze 12 mg; 2. razina doze 8 mg 1., 8., 15. i 22. dana svakog 28- dnevnog ciklusa liječenja.
Dose reduction levels (≤ 75 years of age): Starting dose 40 mg; dose level -1 20 mg; dose level-2 10 mg on Days 1, 8, 15 and 22 of each 28-day treatment cycle.
Razine smanjenja doze (dob ≤75 godina): početna doza 40 mg; 1. razina doze 20 mg; 2. razina doze 10 mg 1., 8., 15. i 22. dana svakog 28- dnevnog ciklusa liječenja.
Dose reduction may be necessary in patients with severe liver impairment in order to maintain the tacrolimus blood trough levels within the recommended target range.
Oštećenje jetre: Možda bude potrebno sniziti dozu u bolesnika s teškim oštećenjem jetre kako bi se najniže koncentracije takrolimusa u krvi održale unutar preporučenog ciljnog raspona.
Dose reduction may be needed for co-administered medicinal products that are predominantly metabolised by CYP3A and CYP2C9.
Moglo bi biti potrebno smanjenje doze za istodobno primijenjene lijekove koji se pretežno metaboliziraju pomoću CYP3A i CYP2C9.
Dose reduction needs to be considered followed by individual dosage adjustment based on the glycaemic response.
Potrebno je razmotriti smanjenje doze, nakon čega slijedi individualna prilagodba doze na osnovi glikemijskog odgovora.
Dose reduction of
Kod istodobne primjene s
Dose reduction of
Treba razmotriti smanjenje
Dose reduction of alfentanil,
Opijati kratkog djelovanja
Dose reduction of benzodiazepines should be considered.
Fenitoin se može primjenjivati
dose reduction of diltiazem by 50%
doze diltiazema za 50%, a
Dose reduction of Indinavir to 600 mg every 8 hours should be considered.
Treba razmotriti smanjenje doze indinavira na 600 mg svakih 8 sati.
Dose reduction of PegIntron in children and adolescents is accomplished by modifying the recommended dose in a two-step process from the original starting dose of 60 µg/m2/week, to 40 µg/m2/week, then to 20 µg/m2/week, if needed.
Smanjivanje doze lijeka PegIntron u djece i adolescenata postiže se prilagodbom preporučene doze u dva koraka: od početne doze od 60 μg/m2 na tjedan na 40 μg/m2 na tjedan, a zatim na 20 μg/m2 na tjedan, ako je potrebno.
Dose reduction of PegIntron in children and adolescents is accomplished by modifying the recommended dose in a two-step process from the original starting dose of 60 g/m2/week, to 40 g/m2/week, then to 20 g/m2/week, if needed.
Smanjivanje doze lijeka PegIntron u djece i adolescenata postiže se prilagodbom preporučene doze u dva koraka: od početne doze od 60 μg/m2 na tjedan na 40 μg/m2 na tjedan, a zatim na 20 μg/m2 na tjedan, ako je potrebno.
Dose reduction of rifabutin
Smanjenje doze rifabutina i
Dose reduction of Sovaldi is not recommended.
Ne preporučuje se sniženje doze Sovaldija.
Dose reduction of sulfonylureas should be considered.
Treba razmotriti smanjenje doze statina.
dose reduction of the beta-blocker
smanjenje doze beta-blokatora.
Dose reduction of vinca alkaloids should be considered.
Nije potrebna prilagodba doze.
Dose reduction of ViraferonPeg in children and adolescents is accomplished by modifying the recommended dose in a two-step process from the original starting dose of 60 g/m2/week, to 40 g/m2/week, then to 20 g/m2/week, if needed.
Smanjivanje doze lijeka ViraferonPeg u djece i adolescenata postiže se prilagodbom preporučene doze u dva koraka: od početne doze od 60 μg/m2 na tjedan na 40 μg/m2 na tjedan, a zatim na 20 μg/m2 na tjedan, ako je potrebno.
Dose reduction or treatment interruption for severe neutropenia and thrombocytopenia are recommended as indicated in the table below.
U slučaju teške neutropenije i trombocitopenije preporučuje se dozu smanjiti ili prekinuti liječenje, kao što je prikazano u donjoj tablici.
Dose reduction recommendations
Preporučeno smanjenje doze
Dose reduction schedule (Starting dose is 3.6 mg/kg)
Raspored smanjivanja doze (početna doza je 3,6 mg/kg)
Dose reduction should be considered in elderly patients due to reduced liver and kidney function as well as lower folate reserves which occur with increased age (see sections 4.4, 4.5, 4.8 or 5.2)
U starijih bolesnika potrebno je razmotriti sniženje doze zbog smanjene funkcije jetre i bubrega, kao i manjih rezervi folata, koji nastaju s uznapredovalnom dobi (vidjeti dijelove 4.4, 4.5, 4.8 ili 5.2)
Dose reduction to 30 mg only
Smanjenje doze samo na 30 mg
Dose reduction to 90 micrograms is recommended if the platelet count is < 50,000/mm3.
Smanjenje doze na 90 mikrograma preporučuje se ako je razina trombocita <50 000/mm3.
Dose reduction/tapered discontinuation should be considered if such symptoms develop.
Ako se pojave takvi simptomi, potrebno je razmisliti o sniženju doze / postupnom ukidanju lijeka.
Dose reduction/tapered discontinuation should be considered if such symptoms develop.
Ako se takvi simptomi razviju treba razmisliti o sniženju doze ili postupnom isključenju lijeka.
Dose reduction/tapered discontinuation should be considered if such symptoms develop.
U slučaju da se takvi simptomi jave treba razmisliti o sniženju doze ili postupnom ukidanju lijeka.
Dose reductions and dose interruptions due to an AE occurred in 59.8% and 70%, respectively, of cabozantinib-treated patients in the pivotal clinical trial.
Zbog nuspojava je doza smanjena u 59,8 %, a doziranje prekinuto u 70 % bolesnika liječenih kabozantinibom u pivotalnom kliničkom ispitivanju.
Dose reductions and dose interruptions occurred in 79% and 72%, respectively, of cabozantinib-treated patients in the pivotal clinical trial.
Smanjenje doze i prekidi doza su se javili u 79%, odnosno 72 % bolesnika koji su liječeni kabozantinibom tijekom ključnog kliničkog ispitivanja.
Dose reductions are not recommended for Perjeta.
Ne preporučuje se smanjivati dozu lijeka Perjeta.
Dose reductions are permitted to a minimum dose of 20 mg/m2/dose twice daily.
Smanjenja doze su dozvoljena do minimalne doze od 20 mg/m2/dozi primjenjeno dva puta dnevno.
Dose reductions are recommended for events that, if persistent, could become serious or intolerable.
Smanjenje doze se preporučuje u događajimakoji, ako potraju, mogu postati ozbiljniili nepodnošljivi.
Dose reductions due to observed hypoglycaemia or suspected Somogyi effect (rebound hyperglycaemia) may be of 50% or higher.
Doza se može smanjiti za 50% ili više ako se opazi hipoglikemija ili u slučaju sumnje na Somogyijev učinak (povratna hiperglikemija).
Dose reductions of colchicine may be required.
Može biti potrebno smanjiti dozu kolhicina.
Dose reductions on the daily dose by 25 mg should be considered if platelet counts exceed the required target.
Ako broj trombocita prijeđe zadanu vrijednost treba se razmotriti smanjivanje dnevne doze za 25 mg.
Dose reductions should be considered if the platelet count decreases below 100,000/mm3, with the goal of avoiding dose interruptions for thrombocytopenia.
Treba razmotriti smanjivanje doze ako se razina trombocita snizi na manje od 100 000/mm3, kako bi se izbjegao prekid u doziranju zbog trombocitopenije.
Dose reductions were noted to slow or stop the progression of splenic enlargement, and in 3% of patients a splenectomy was required.
Pokazalo se da se povećanje slezene usporava ili zaustavlja smanjenjem doze, a u 3% bolesnika bila je potrebna splenektomija.
Dose reductions were noted to slow or stop the progression of splenic enlargement, and in 3% of patients a splenectomy was required.
Primijećeno je da smanjenje doze usporava ili zaustavlja progresiju povećanja slezene, a u 3 % bolesnika bila je potrebna splenektomija.
Dose regime n
Režim doziranja
Dose regimen2
Režim doziranja2
Dose required (micrograms)
Potrebna doza (mikrogrami)
dose ritonavir (100 mg, once or twice
telaprevir/efavirenz (1125 mg svakih 8h/600 mg jedanput na dan)
dose ritonavir and simeprevir.
imeprevirom.
dose ritonavir and telaprevir
ritonavira i telaprevira
dose ritonavir it may cause a large increase
dozom ritonavira to može izazvati velik
dose ritonavir, is not recommended
dozom ritonavira (vidjeti dio 4.4).
Dose scale
kala za doziranje
Dose Schedule of MIRAPEXIN
Raspored doziranja MIRAPEXINA
Dose Schedule of SIFROL
Raspored doziranja SIFROLA
Dose scheme for the maintenance dose:
Shema doza za dozu održavanja:
Dose selection and dosing:
Odabir doze i doziranje:
Dose selection and reconstitution of the vials
Odabir doze i priprema otopine u bočicama
Dose selection and reconstitution of the vials
Odabir doze i rekonstitucija otopine u bočicama
Dose selector
Izbornik
Dose Selector dial
Kružni izbornik doze
Dose selector Push- button
Izbornik doze Potisni gumb
dose setting knob
tipka za podešavanje doze